Alexander Lesokhin, MD: Can Patients With Relapsed/Refractory Multiple Myeloma Successfully Pause or Discontinue Elranatamab?
ASH 2025
Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses results of a retrospective analysis from the phase II MagnetisMM-3 trial. A post hoc analysis was conducted of the subgroup of patients enrolled in the study who had a prolonged treatment interruption or who permanently discontinued elranatamab and maintained their responses for 6 months or longer (Abstract 2269).
The ASCO Post Staff
Dory Abelman, PhD(c), HBHSc, of the University of Toronto, discusses findings that support the feasibility of ultradeep cell-free DNA whole-genome sequencing for comprehensive genomic profiling in patients with multiple myeloma, which may be a less invasive alternative to bone marrow biopsy (Abstract 495).
The ASCO Post Staff
Jayastu Senapati, MBBS, of The University of Texas MD Anderson Cancer Center, presents initial results from a phase II trial of brexucabtagene autoleucel as consolidation therapy in front-line high-risk B-cell acute lymphoblastic leukemia (B-ALL) or relapsed/refractory B-ALL after cytoreduction (Abstract 1573).
The ASCO Post Staff
Krina Patel, MD, MSc, of The University of Texas MD Anderson Cancer Center, provides updated results from the fully enrolled, ongoing iMMagine-1 phase II registrational trial of anitocabtagene autoleucel, an autologous anti-BCMA CAR T-cell therapy with a novel D-domain binder. The agent is under development for patients with relapsed and/or refractory multiple myeloma (Abstract 256).
The ASCO Post Staff
Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)—and could challenge the current treatment standard (Abstract 6).
The ASCO Post Staff
Othman Al-Sawaf, MD, PhD, of the University Hospital of Cologne, presents results from the phase III CLL17 trial, which compared continuous ibrutinib monotherapy to fixed-duration venetoclax plus obinutuzumab to fixed-duration venetoclax plus ibrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL) (Abstract 1).
